Revenue
2025
Nasus Pharma Ltd (NSRX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $1.24B | — | — |
| Research & development | $2.2M | $335,000 | $567,000 |
| Operating expenses | $4.9M | $1.1M | $1.1M |
| Operating income | −$4.9M | −$1.1M | −$1.1M |
| Net income | −$5.9M | −$1.5M | −$1.1M |
| Basic EPSper diluted share | -$0.72 | -$0.22 | -$0.15 |
| Diluted EPSper diluted share | -$0.72 | -$0.22 | -$0.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | Teleman Dan BenjaminChief Executive Officer | BuyOrdinary Shares | 6.5K | $3.10 | $20.3K | 163.5K |
| Apr 22, 2026Form 4 | Teleman Dan BenjaminChief Executive Officer | BuyOrdinary Shares | 2.9K | $3.76 | $10.9K | 157.0K |
| Mar 31, 2026Form 4 | Teleman Dan BenjaminChief Executive Officer | BuyOrdinary Shares | 15.0K | $2.04 | $30.6K | 21.2K |